News

2012 Top 10 Advances in Heart Disease and Stroke Research

Resuscitation, cell regeneration, a new high blood pressure treatment and developments in devices for treating stroke are among the key scientific findings that make up this year's top...

December 19, 2012 — The first patient has been enrolled in the Boston Scientific EVOLVE II clinical trial, which is designed to further assess the safety and effectiveness of the Synergy ...

Cook, Zilver PTX, stent, expanding, delivery sheath

The U.S. Food and Drug Administration (FDA) granted market clearance for Cook Medical’s Zilver PTX drug-eluting peripheral stent. It is the first device of its kind on several fronts to go...

Boston Scientific Promus Element Plus Promus Element Drug Eluting Stent

November 9, 2012 — Boston Scientific Corp. has received approval to update the directions for use (DFU) labeling for Promus Element and Promus Element Plus coronary drug eluting stent (DES)...

October 31, 2012 — Boston Scientific Corp. received CE mark approval for the Synergy everolimus-eluting...

The Cardiovascular Research Foundation (CRF) announced the late-breaking trials and first report investigations that will be presented at next month's ...

As the average age of the U.S. population and the number of patients at high risk for cardiovascular disease increase, the usage of cardio and endovascular stents continues to grow. Interventional...

June 21, 2012 — Plans for a new study involving BioFreedom, the polymer-free drug-coated stent (DCS) from Biosensors, were announced  at EuroPCR by principal investigator Dr. Philip Urban,...

June 15, 2012 — Stentys SA, a medical technology company commercializing the world's first and only self-apposing stent to treat acute myocardial infarction (AMI), announced that it has...

Evaluating the performance of your cath lab is key to developing a strategic plan for improving service offerings, planning growth and expanding market share to compete for revenues. Availability...

June 4, 2012 — Boston Scientific Corp. has received U.S. Food and Drug Administration (FDA) regulatory approval of 32 mm and 38 mm lengths for the Promus Element Plus everolimus-eluting...

May 30, 2012 - According to study results to be featured in the late-breaking clinical trials session at the American Association of Clinical Endocrinologists (AACE) 21st Annual Scientific...

May 23, 2012 — Boston Scientific Corp. announces that the Synergy everolimus-eluting bioabsorbable polymer-coated platinum chromium coronary stent demonstrated noninferior results in treating...

May 23, 2012 — Boston Scientific Corp. announced two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm Promus Element...

May 22, 2012 — New long-term data from the DIVERGE study presented at EuroPCR 2012 showed that the use of the Axxess...

May 15, 2012 –– As EuroPCR 2012 gets underway, Medtronic Inc.announced that the Resolute Integrity Coronary Stent System has received European regulatory approval for several new indications...

April 12, 2012 – Abbott announced approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the next-generation Xience Prime Everolimus-Eluting Coronary Stent System for the...

April 6, 2012 — Boston Scientific Corp. announced results from a quantitative coronary angiographic (QCA) analysis of the incidence of longitudinal stent deformation in the PERSEUS and PLATINUM...

Boston Scientific announced its support of the HORIZONS II AMI clinical trial, which is designed to evaluate the safety and efficacy of the Promus Element Plus everolimus-eluting platinum chromium...